Genetic Signatures Limited (ASX: GSS) announced today that it has resolved not to proceed with its proposed merger with Microba Life Sciences Limited (ASX: MAP). The decision comes in light of Microba’s notification that it lacks the financial capacity to complete the Proposed Merger without securing additional capital. Genetic Signatures is a specialist molecular diagnostics company focused on the development and commercialisation of its proprietary platform technology, 3base®. The company designs and manufactures PCR-based products for the routine detection of infectious diseases under the EasyScreen™ brand. This announcement follows an update to the commercial terms disclosed on 21 October 2026, and Microba’s subsequent request for a voluntary suspension of trading in its shares on 17 November 2026.
After extensive discussions, engagement, and due diligence conducted over many months, GSS concluded that the merger was no longer viable. The company noted that both GSS and Microba had invested significant time and effort into pursuing the combination. However, Microba’s inability to proceed without securing further capital was the pivotal factor in GSS’s resolution to cease pursuing the Proposed Merger.
GSS also confirmed it had engaged in discussions with Microba regarding the potential provision of unsecured debt funding to support Microba’s working capital needs during the merger’s implementation. Ultimately, the GSS Board determined against such an arrangement, citing associated risks and potential regulatory requirements. Genetic Signatures will issue a separate announcement shortly to formally withdraw Resolution 4 from the agenda of its upcoming Annual General Meeting, scheduled for 30 November 2026. A further market announcement will also address the impact of this decision and the withdrawal of Resolution 4 on the Takeovers Panel Application initiated by BCAL Diagnostics Limited on 13 November 2026.
